{"id":7250,"date":"2013-07-23T19:04:00","date_gmt":"2013-07-24T00:04:00","guid":{"rendered":"http:\/\/medicinainterna.com.mx\/?p=7250"},"modified":"2013-07-23T19:04:00","modified_gmt":"2013-07-24T00:04:00","slug":"criterios-eortc-para-grupos-de-riesgo-con-enfermedad-localizada","status":"publish","type":"post","link":"https:\/\/medicinainterna.com.mx\/?p=7250","title":{"rendered":"Criterios EORTC para grupos de riesgo con Enfermedad Localizada."},"content":{"rendered":"<h3><\/h3>\n<table width=\"287\" border=\"1\" cellspacing=\"0\" cellpadding=\"0\">\n<tbody>\n<tr>\n<td valign=\"top\" width=\"147\"><i>Subgrupo favorable<\/i><\/td>\n<td valign=\"top\" width=\"140\"><i>Subgrupo desfavorable<\/i><\/td>\n<\/tr>\n<tr>\n<td valign=\"top\" width=\"147\">Estadio I y II con 3 o menos areas nodales afectas, y edad menor de 50 a\u00f1os, y<\/p>\n<p>MT (ratio Mediastino\/T\u00f3rax) menor 0.33, y<\/p>\n<p>VSG menor de 50 sin s\u00edntomas B,<\/p>\n<p>o<\/p>\n<p>VSG menor de 30 con s\u00edntomas B.<\/td>\n<td valign=\"top\" width=\"140\">Estadio II con 4 o m\u00e1s areas nodales afectas, o<\/p>\n<p>edad igual o mayor de 50 a\u00f1os, o<\/p>\n<p>ratio MT igual o mayor de 0.33, o<\/p>\n<p>VSG igual o mayor de 50 sin s\u00edntomas B,<\/p>\n<p>o<\/p>\n<p>VSG igual o mayor de 30 con s\u00edntomas B.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Fuente: Eghbali H, Raemaekers J, Carde P; EORTC Lymphoma Group. The EORTC strategy in the treatment of Hodgkin\u2032s lymphoma. Eur J Haematol Suppl. 2005;(66):135-40.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Subgrupo favorable Subgrupo desfavorable Estadio I y II con 3 o menos areas nodales afectas, y edad menor de 50 a\u00f1os, y MT (ratio Mediastino\/T\u00f3rax) menor 0.33, y VSG menor de 50 sin s\u00edntomas B, o VSG menor de 30 con s\u00edntomas B. Estadio II con 4 o m\u00e1s areas nodales afectas, o edad igual &hellip; <a href=\"https:\/\/medicinainterna.com.mx\/?p=7250\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Criterios EORTC para grupos de riesgo con Enfermedad Localizada.&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[9],"tags":[],"class_list":["post-7250","post","type-post","status-publish","format-standard","hentry","category-hematologia"],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/medicinainterna.com.mx\/index.php?rest_route=\/wp\/v2\/posts\/7250","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medicinainterna.com.mx\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medicinainterna.com.mx\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medicinainterna.com.mx\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/medicinainterna.com.mx\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=7250"}],"version-history":[{"count":0,"href":"https:\/\/medicinainterna.com.mx\/index.php?rest_route=\/wp\/v2\/posts\/7250\/revisions"}],"wp:attachment":[{"href":"https:\/\/medicinainterna.com.mx\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=7250"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medicinainterna.com.mx\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=7250"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medicinainterna.com.mx\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=7250"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}